A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Amphotericin B (Primary)
- Indications Cryptococcal meningitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ORACLE
- Sponsors Matinas BioPharma
- 06 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Dec 2017 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 05 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.